Swanbio Therapeutics, Inc.
Clinical trials sponsored by Swanbio Therapeutics, Inc., explained in plain language.
-
Spinal injection gene therapy tested for rare nerve disease
Disease control TerminatedThis study tested a one-time gene therapy injection into the spinal fluid for adults with a rare, progressive nerve disease called adrenomyeloneuropathy (AMN). The goal was to see if delivering a working copy of a faulty gene could be safe and potentially slow down the worsening …
Phase: PHASE1, PHASE2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists track rare nerve disease to pave way for future treatments
Knowledge-focused TerminatedThis study aimed to better understand how disabilities from Adrenomyeloneuropathy (AMN) change over time in adults. Researchers observed 65 adult men with AMN to track their walking ability and quality of life. The goal was to gather information to help design future treatment tr…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Mar 18, 2026 18:25 UTC